AUSTIN, Texas, March 16, 2015 /PRNewswire/ -- Savara Pharmaceuticals today announced that Rob Neville, Chief Executive Officer, will present at the 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015 at 8:30 a.m. ET. The conference will take place at the Millennium Broadway Hotel & Conference Center in New York City.
Mr. Neville's corporate overview will include recently reported positive topline results from Savara's Phase 2 clinical trial of AeroVanc, the first inhaled antibiotic being developed to address the growing problem of methicillin-resistant Staphylococcus aureus lung infection in people with cystic fibrosis.
AeroVanc is an investigational, proprietary inhaled dry powder form of vancomycin in a capsule-based device designed for convenient self-administration. By delivering vancomycin directly to the lungs, higher vancomycin concentrations are achieved at the site of infection, which is expected to lead to improved clinical efficacy. In addition, direct delivery of the drug into the lungs reduces exposure to the drug elsewhere in the body, and is expected to reduce the risk of systemic drug-related side effects. AeroVanc has received from the U.S. Food and Drug Administration Fast Track and Orphan Drug designations as well as Qualified Infectious Disease Product (QIDP) status providing 12 years of market exclusivity.
About Savara Pharmaceuticals
Savara Pharmaceuticals is a specialty pharmaceutical company focusing on innovative drugs for the treatment of serious and life-threatening rare respiratory diseases. The company's lead product, AeroVanc, is the first dry powder inhaled antibiotic being developed for the treatment of MRSA infection in people with cystic fibrosis. For more information, please see Savara's website at www.savarapharma.com, or www.aerovanc.com, or find us on Twitter, Facebook and LinkedIn.
Robert Neville, CEO
SOURCE Savara Pharmaceuticals